Encorafenib/Cetuximab Plus mFOLFOX6 Provides New SOC for BRAF V600E+ mCRC
Scott Kopetz, MD, PhD, FACP, highlights the efficacy of encorafenib/cetuximab with mFOLFOX6 in BRAF V600E–mutated metastatic colorectal cancer.
Related Articles
The Dual Nature of Cancer Treatment: Episode 2
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
Personalizing Lung Cancer Treatment Reduces Toxicity and Improves Cure Rates
New lung cancer treatment options have emerged, and several groups are exploring treatment strategies that omit chemotherapy for locally advanced NSCLC.
RAS(ON) Inhibitors May Overcome Resistance to Traditional KRAS Inhibitors in Solid Tumors
Study investigators are aiming to leverage therapy resistance, particularly in patients with solid tumors after receiving available RAS inhibitors.
Dasatinib Plus CAR T-Cell Therapy Shows Efficacy in Ph+ Acute Lymphoblastic Leukemia
Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.
MRD-Guided Zanubrutinib/Venetoclax/Obinutuzumab Triplet Induces Deep Remissions in R/R CLL
Zanubrutinib plus venetoclax and obinutuzumab was well tolerated—aside from COVID-19–related toxicities—in patients with relapsed/refractory CLL.
Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making
Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.
Molecular Profiling, Endocrine Sensitivity Are Key to Managing Later-Line HR+/HER2-Negative Breast Cancer
Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.
Pembrolizumab-Based Regimens Gain Ground in TNBC Management
Nerea Lopetegui-Lia, MD, discusses the prevalence of and risk factors for triple-negative breast cancer, and strategies that may improve survival outcomes.
CCTG BR.31 Data Show Adjuvant Durvalumab Does Not Alter Relapse Frequency or Patterns in Resected NSCLC
Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.
Evaluating Early Treatment Response in CML: Expert Insights on Monitoring
Panelists discuss how in standard clinical practice, response to first-line tyrosine kinase inhibitor therapy is monitored through regular molecular testing of BCR::ABL1 transcript levels, with…